Day: August 9, 2021
Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio
Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payments, together with additional tiered royalties; HUTCHMED to receive development and commercial rights to TAZVERIK® in Greater China
HUTCHMED to host a webcast and call on Monday August 9, at 9:30 a.m. EDT / 2:30 p.m. BST / 9:30 p.m. HKT – see www.hutch-med.com/event for details
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and CAMBRIDGE, Mass, Aug. 08, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Epizyme, Inc. (“Epizyme”) (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel...